secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2022-09-16T23:59:59+00:00
Accession:  0001171843-22-006126
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose appoints Dr. Bernd R. Seizinger to its Board of Directors, effective Sept. 13, 2022
--------------------------------------------------------------------------------

- Dr. Seizinger brings >25 years pharma/biotech experience, including VP roles at Bristol-Myers Squibb.
- He will receive standard non-management director compensation and a 50,000-share option grant under the 2021 plan.
- Board now has seven members; appointment effective immediately.
- Seizinger has served as CEO of GPC Biotech and holds board positions at multiple biotech firms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184322006126/0001171843-22-006126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184322006126/f8k_091622.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-006126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer